Search

Your search keyword '"Renal cell carcinoma -- Physiological aspects"' showing total 19 results
Start Over Descriptor "Renal cell carcinoma -- Physiological aspects"
19 results on '"Renal cell carcinoma -- Physiological aspects"'

1. Targeting renal cell carcinoma with a HIF-2 antagonist

Author

Chen, Wenfang, Hill, Haley, Christie, Alana, Kim, Min Soo, Holloman, Eboni, Pavia-Jimenez, Andrea, Homayoun, Farrah, Ma, Yuanqing, Patel, Nirav, Yell, Paul, Hao, Guiyang, Yousuf, Qurratulain, Joyce, Allison, Pedrosa, Ivan, Geiger, Heather, Zhang, He, Chang, Jenny, Gardner, Kevin H., Bruick, Richard K., Reeves, Catherine, Hwang, Tae Hyun, Courtney, Kevin, Frenkel, Eugene, Sun, Xiankai, Zojwalla, Naseem, Wong, Tai, Rizzi, James P., Wallace, Eli M., Josey, John A., Xie, Yang, Xie, Xian-Jin, Kapur, Payal, McKay, Rene M., and Brugarolas, James

Subjects
Physiological aspects, Methods, Molecular targeted therapy -- Methods, Renal cell carcinoma -- Physiological aspects, Transcription factors -- Physiological aspects
Abstract

Author(s): Wenfang Chen [1, 2, 3]; Haley Hill [1, 2]; Alana Christie [1]; Min Soo Kim [1, 4]; Eboni Holloman [1, 2]; Andrea Pavia-Jimenez [1, 2]; Farrah Homayoun [1, 2]; [...]

Published
2016
Full Text
View/download PDF

2. New Kidney Cancer Data Have Been Reported by Researchers at Affiliated Hospital of Hubei University of Arts and Science (6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent ...)

Subjects
Physiological aspects, Physical fitness -- Physiological aspects, Cancer research -- Physiological aspects, Chemotherapy -- Physiological aspects, Renal cell carcinoma -- Physiological aspects
Abstract

2020 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Oncology - Kidney Cancer are presented in a new [...]

Published
2020

3. SETD2 deficiency impairs b-catenin destruction complex to facilitate renal cell carcinoma formation

Subjects
Physiological aspects, Physical fitness -- Physiological aspects, Methylation -- Physiological aspects, Methyltransferases -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Histones -- Physiological aspects
Abstract

2020 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2020

4. Researchers at Division of Endocrinology and Metabolism Target Thyroid Cancer (Intermixed medullary and papillary thyroid cancer in a patient with renal cell carcinoma)

Subjects
Physiological aspects, Thyroid cancer -- Physiological aspects, Physical fitness -- Physiological aspects, Cancer -- Physiological aspects, Cancer research -- Physiological aspects, Thyroid gland -- Physiological aspects, Renal cell carcinoma -- Physiological aspects
Abstract

2020 JUN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on thyroid cancer are discussed in a new report. According [...]

Published
2020

5. Reports from Second Affiliated Hospital Describe Recent Advances in Apoptosis (Morusin Exerts Anti-cancer Activity In Renal Cell Carcinoma By Disturbing Mapk Signaling Pathways)

Subjects
Physiological aspects, Cancer treatment -- Physiological aspects, Apoptosis -- Physiological aspects, Physical fitness -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Obesity, Anopheles, Carcinoma, Cancer, Flavonoids, Finance, Tumors, Editors
Abstract

2020 MAY 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Cellular Physiology - Apoptosis. According to news [...]

Published
2020

6. Data from Jeju National University Provide New Insights into Carcinomas (Yeast extract inhibits the proliferation of renal cell carcinoma cells via regulation of iron metabolism)

Subjects
Physiological aspects, Physical fitness -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Obesity, Carcinoma, Cancer, Tumors, Editors
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Carcinomas have been presented. According to news [...]

Published
2019

7. Rogosin Institute Researchers Broaden Understanding of Carcinomas (FOXD1 regulates cell division in clear cell renal cell carcinoma)

Subjects
Physiological aspects, Cancer -- Physiological aspects, Biochemistry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Carcinoma, Renal cell -- Physiological aspects
Abstract

2021 APR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on carcinomas have been presented. According to news originating from the [...]

Published
2021

8. Investigators at Shanghai Jiao-Tong University Have Reported New Data on Carcinomas (c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma)

Subjects
Physiological aspects, Physical fitness -- Physiological aspects, Glucose -- Physiological aspects, Glucose metabolism -- Physiological aspects, Renal cell carcinoma -- Physiological aspects
Abstract

2017 JAN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Carcinomas have been published. According to [...]

Published
2017

9. Studies from Qingdao University Have Provided New Information about Apoptosis (Holliday Junction-recognition Protein Modulates Apoptosis, Cell Cycle Arrest and Reactive Oxygen Species Stress In Human Renal Cell Carcinoma)

Subjects
Physiological aspects, Apoptosis -- Physiological aspects, Cell cycle -- Physiological aspects, Renal cell carcinoma -- Physiological aspects
Abstract

2020 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Cellular Physiology - Apoptosis is now available. According to [...]

Published
2020

10. Investigators at Sun Yat-Sen University Zero in on Kidney Cancer (The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy)

Subjects
Physiological aspects, Cancer treatment -- Physiological aspects, Immunotherapy -- Physiological aspects, Glycogen -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Antineoplastic agents -- Physiological aspects
Abstract

2020 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Oncology - Kidney Cancer have been presented. According to news [...]

Published
2020

11. Data on Carcinomas Reported by Researchers at Osaka University Graduate School of Medicine (MicroRNA-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma)

Subjects
Physiological aspects, MicroRNA -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Carcinogenesis, Anopheles, Carcinoma, Cancer, Editors
Abstract

2020 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Oncology - Carcinomas have been published. According to news [...]

Published
2020

12. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

13. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

14. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2017

15. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

16. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

17. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

San Francisco: Calithera Biosciences, Inc. has issued the following press release: Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

18. United Kingdom,United States : Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Glutamine -- Physiological aspects, Medical research -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, Business, international, Opdivo (Medication)
Abstract

Bristol-Myers Squibb Company and Calithera Biosciences, Inc, a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for [...]

Published
2016

19. Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma

Subjects
Bristol-Myers Squibb Co., Cancer treatment -- Physiological aspects, Medical research -- Physiological aspects, Biotechnology industries -- Physiological aspects, Pharmaceutical industry -- Physiological aspects, Renal cell carcinoma -- Physiological aspects, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

New York: Bristol-Myers Squibb Company has issued the following news release -Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results